We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Spatial Clustering of Chagas Disease Helps Screening in Peru

By Labmedica staff writers
Posted on 03 Jan 2008
A new targeted-screening strategy could make the diagnosis and treatment of Chagas disease more feasible in low-resource settings. More...
The strategy is based on a study that found that households with infected children were significantly clustered spatially around each other.

Trypanosoma cruzi, the single-cell parasite that causes Chagas disease, is transmitted by triatomine bugs that infest houses in poor communities. The disease, which infects an estimated 11 million people in Latin America, kills more people than any other parasitic disease in the Americas.

Chagas disease control programs have traditionally focused on interrupting the transmission of T. cruzi through vector control measures (such as insecticide spraying), rather than on active case detection and specific treatment of infected people. While control actions have reduced the geographic range and prevalence of major triatomine vectors, without attention to timely diagnosis of those already infected, the window of opportunity for effective treatment (such as giving anti-parasitic drugs) is missed.

A new study has demonstrated an alternative screening strategy that could potentially be much more efficient, cost-effective, and viable in the resource-poor regions plagued by the disease.

Michael Levy of Emory University (Atlanta, GA, USA), the Centers for Disease Control and Prevention, (CDC; Atlanta, GA, USA), currently at the Fogarty International Center of the National Institutes of Health (NIH; Bethesda, MD, USA), and colleagues performed a serological survey in children 2-18 years old living in a peri-urban community of Arequipa, Peru, where a vector control campaign is currently disrupting transmission of T. cruzi. They found that 5.3% of children had already been infected by the time their households received insecticide application. They also found that households with infected children were significantly clustered spatially around each other.

The findings were related to data that had been collected during a vector control campaign that included entomological, spatial, and census data. They found that using such data to target diagnostic testing would have identified over 83% of the infected children while testing only 22% of eligible children (only 22% would have to be tested because of the way the households with infected children clustered).

An important reason for the low rates of treatment in Latin America is that health services and control programs lack sufficient resources for comprehensive blood screening and supervised treatment in the most affected areas. Michael Levy's study showed that that data easily collected during an ongoing insecticide spraying campaign in an urban area could be used to identify children at greatest risk of infection with T. cruzi.


Related Links:
Centers for Disease Control and Prevention
Emory University
Fogarty International Center of the National Institutes of Health

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.